Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beyond Air, Inc. (NASDAQ: XAIR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to official information about this commercial-stage medical device and biopharmaceutical issuer. Beyond Air develops nitric oxide (NO) generators and delivery systems, including the LungFit platform, and pursues NO-based therapeutics in respiratory, neurological, and oncology indications. Its filings provide detailed context on these activities.
Core documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically describe the LungFit PH system, its FDA approval and CE Mark for neonatal hypoxic respiratory failure associated with pulmonary hypertension, the broader LungFit pipeline for severe lung infections, and affiliated programs like Beyond Cancer’s ultra-high concentration NO for solid tumors and NeuroNOS’s small-molecule nNOS inhibitors. Risk factors, R&D narratives, and segment information in these reports help readers understand the company’s NO-focused strategy and development stage.
Current reports on Form 8-K capture material events, including financing agreements such as promissory notes and equity purchase arrangements, warrant inducement transactions, reverse stock split implementation, leadership changes, and transactions involving subsidiaries like NeuroNOS. Registration statements, including Forms S-1 or S-3, outline the terms of securities offerings, equity lines of credit, and resale arrangements for investors like Streeterville Capital.
On this page, Stock Titan supplements raw filings data with AI-powered summaries that highlight key terms, financial obligations, and business implications from lengthy documents. Users can quickly identify items related to capital structure changes, Orphan Drug Designations, or regulatory milestones without reading every page. Real-time updates from EDGAR, combined with structured access to Forms 4 and other ownership reports, allow close monitoring of insider and institutional activity in XAIR. This makes the filings page a practical starting point for due diligence on Beyond Air’s regulatory, financial, and clinical disclosure record.
Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.
Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.
Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.
The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.
Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.
The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.
Beyond Air (XAIR) disclosed an insider derivative change by CEO and Chairman Steven A. Lisi. On 11/03/2025, he canceled 164,778 warrants with a $7.586 exercise price and received a replacement warrant for 164,778 shares at $1.95. The warrant was originally issued on September 27, 2024, became exercisable on November 22, 2024, and will expire five years from November 22, 2024. Following these transactions, he directly holds 164,778 warrants.
Beyond Air (XAIR) announced new financing and equity arrangements. The company entered an equity purchase agreement with Streeterville Capital for up to
Beyond Air also issued a secured promissory note with a principal amount of
The company amended a prior loan to add a
Beyond Air, Inc. (XAIR) filed an S-3 shelf registration that includes an At-The-Market (ATM) equity program with BTIG allowing up to $35,000,000 of Common Stock sales. The company agreed to pay the agent a 3.0% cash commission and reimburse certain expenses. Reported issuances under the ATM were 564,699 shares for $2.5 million during the quarter ended June 30, 2025, and 1,877,076 shares for $5.8 million from July 1, 2025 through September 24, 2025. The prospectus includes standard risk-factor language noting the company expects to incur losses for the next few years and lists typical commercialization, regulatory, intellectual property, personnel, and growth-management risks.
Beyond Air, Inc. filed an 8-K describing terms that limit the number of common shares issuable on exercise of certain warrants to prevent a holder from exceeding a stated "Beneficial Ownership Limitation." If an exercise would push the holder past that limit, the company will only issue the number of shares that keep the holder below the limit and will hold the remaining shares in abeyance until the holder notifies the company that issuance would comply with the limitation.
The filing lists exhibits including a Form of New Warrant, a Form of Inducement Letter, and a Press Release dated September 8, 2025. The filing also identifies Steven A. Lisi by name.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
